Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies

[1]  Cedric E. Ginestet,et al.  Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level , 2021, JAMA psychiatry.

[2]  J. Lieberman,et al.  An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS , 2020, Schizophrenia Research.

[3]  O. Howes,et al.  Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis , 2020, Neuroscience & Biobehavioral Reviews.

[4]  F. Schlagenhauf,et al.  Glutamate in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: A Meta-analysis of 1H-Magnetic Resonance Spectroscopy Studies , 2020, Biological Psychiatry.

[5]  Valerie J. Sydnor,et al.  A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk , 2020, Schizophrenia Research.

[6]  F. Schlagenhauf,et al.  Glutamate in Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: A Meta-Analysis of 1-HMRS Studies , 2020, Biological Psychiatry.

[7]  Linda Chang,et al.  Motion correction in magnetic resonance spectroscopy , 2020, Magnetic resonance in medicine.

[8]  P. Williamson,et al.  Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate , 2020, Molecular Psychiatry.

[9]  G. Remington,et al.  Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. , 2020, Journal of psychiatric research.

[10]  S. Dienel,et al.  Markers of glutamate and GABA neurotransmission in the prefrontal cortex of schizophrenia subjects: Disease effects differ across anatomical levels of resolution , 2020, Schizophrenia Research.

[11]  F. Schlagenhauf,et al.  Association of Cortical Glutamate and Working Memory Activation in Patients With Schizophrenia: A Multimodal Proton Magnetic Resonance Spectroscopy and Functional Magnetic Resonance Imaging Study , 2020, Biological Psychiatry.

[12]  A. Lahti,et al.  Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients , 2020, Translational Psychiatry.

[13]  E. Rostrup,et al.  Cerebral Glutamate and Gamma-Aminobutyric Acid Levels in Individuals at Ultra-high Risk for Psychosis and the Association With Clinical Symptoms and Cognition. , 2019, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[14]  G. Remington,et al.  Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study , 2019, Neuropsychopharmacology.

[15]  J. Ragland,et al.  Disrupted GABAergic facilitation of working memory performance in people with schizophrenia , 2019, NeuroImage: Clinical.

[16]  O. Howes,et al.  Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion , 2019, European Neuropsychopharmacology.

[17]  R. Poppi,et al.  Peripheral biomarkers allow differential diagnosis between schizophrenia and bipolar disorder. , 2019, Journal of psychiatric research.

[18]  A. Egerton,et al.  Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia , 2019, Psychopharmacology.

[19]  Jong H. Yoon,et al.  Reduced in vivo visual cortex GABA in schizophrenia, a replication in a recent onset sample , 2019, Schizophrenia Research.

[20]  T. Schneider-Axmann,et al.  The impact of endurance training and table soccer on brain metabolites in schizophrenia , 2019, Brain Imaging and Behavior.

[21]  J. Théberge,et al.  Glutamate and Dysconnection in the Salience Network: Neurochemical, Effective Connectivity, and Computational Evidence in Schizophrenia , 2019, Biological Psychiatry.

[22]  B. O’Donnell,et al.  Relationship of auditory electrophysiological responses to magnetic resonance spectroscopy metabolites in Early Phase Psychosis. , 2019, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[23]  Josef J. Bless,et al.  Intra-Regional Glu-GABA vs Inter-Regional Glu-Glu Imbalance: A 1H-MRS Study of the Neurochemistry of Auditory Verbal Hallucinations in Schizophrenia , 2019, Schizophrenia bulletin.

[24]  A. Grace,et al.  Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study , 2019, Neuropsychopharmacology.

[25]  S. Small,et al.  Hippocampal Pathology in Clinical High-Risk Patients and the Onset of Schizophrenia , 2019, Biological Psychiatry.

[26]  N. Horita,et al.  Treatment effects on neurometabolite levels in schizophrenia: A systematic review and meta-analysis of proton magnetic resonance spectroscopy studies , 2019, Schizophrenia Research.

[27]  E. Rostrup,et al.  Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis , 2019, Psychological Medicine.

[28]  M. Caan,et al.  Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: A placebo controlled, cross-over study , 2019, Psychiatry Research: Neuroimaging.

[29]  Michael F. Green,et al.  Brain glutathione levels and age at onset of illness in chronic schizophrenia , 2019, Acta Neuropsychiatrica.

[30]  A. Lahti,et al.  A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia , 2019, Schizophrenia Research.

[31]  O. Howes,et al.  Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study , 2019, Scientific Reports.

[32]  Karl J. Friston,et al.  Oscillatory, Computational, and Behavioral Evidence for Impaired GABAergic Inhibition in Schizophrenia , 2019, Schizophrenia bulletin.

[33]  R. Kahn,et al.  Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate , 2019, npj Schizophrenia.

[34]  F. Piras,et al.  Cerebellar GABAergic correlates of cognition‐mediated verbal fluency in physiology and schizophrenia , 2019, Acta psychiatrica Scandinavica.

[35]  S. A. Wijtenburg,et al.  Brain insulin resistance and altered brain glucose are related to memory impairments in schizophrenia , 2019, Schizophrenia Research.

[36]  I. Hickie,et al.  Elucidating the glutamatergic processes underlying mismatch negativity deficits in early stage bipolar disorder and schizophrenia: A combined 1H-MRS and EEG study. , 2019, Journal of psychiatric research.

[37]  Steven C. R. Williams,et al.  Neurochemical effects of oxytocin in people at clinical high risk for psychosis , 2019, European Neuropsychopharmacology.

[38]  X. Mao,et al.  Striatal Glutathione in First-episode Psychosis Patients Measured In Vivo with Proton Magnetic Resonance Spectroscopy. , 2019, Archives of medical research.

[39]  D. Javitt,et al.  Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study , 2019, Psychiatry Research.

[40]  J. Théberge,et al.  Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione , 2019, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[41]  A. Szulc,et al.  Proton magnetic resonance spectroscopy changes in a longitudinal schizophrenia study: a pilot study in eleven patients , 2019, Neuropsychiatric disease and treatment.

[42]  G. Remington,et al.  Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study , 2019, Biological Psychiatry.

[43]  Jennifer M. Coughlin,et al.  Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis , 2019, JAMA psychiatry.

[44]  Alan A. Wilson,et al.  GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. , 2019, Journal of psychiatry & neuroscience : JPN.

[45]  J. Bustillo,et al.  Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia. , 2019, Journal of affective disorders.

[46]  A. Egerton,et al.  Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications , 2019, Psychopharmacology.

[47]  Dengtang Liu,et al.  Modular Functional-Metabolic Coupling Alterations of Frontoparietal Network in Schizophrenia Patients , 2019, Front. Neurosci..

[48]  T. Gawne,et al.  Relationship Between Cortical Excitation and Inhibition and Task-Induced Activation and Deactivation: A Combined Magnetic Resonance Spectroscopy and Functional Magnetic Resonance Imaging Study at 7T in First-Episode Psychosis. , 2019, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[49]  A. Young,et al.  Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task , 2019, European Neuropsychopharmacology.

[50]  P. McGuire,et al.  Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis , 2019, JAMA psychiatry.

[51]  Chunbo Li,et al.  Effect of Electroconvulsive Therapy on Medial Prefrontal &ggr;-Aminobutyric Acid Among Schizophrenia Patients: A Proton Magnetic Resonance Spectroscopy Study , 2018, The journal of ECT.

[52]  A. Lahti,et al.  A Longitudinal Multimodal Neuroimaging Study to Examine Relationships Between Resting State Glutamate and Task Related BOLD Response in Schizophrenia , 2018, Front. Psychiatry.

[53]  R. Milewski,et al.  Choline Compounds of the Frontal Lobe and Temporal Glutamatergic System in Bipolar and Schizophrenia Proton Magnetic Resonance Spectroscopy Study , 2018, Disease markers.

[54]  A. Lahti,et al.  Neurometabolic abnormalities in the associative striatum in antipsychotic-naïve first episode psychosis patients , 2018, Psychiatry Research: Neuroimaging.

[55]  A. Griffa,et al.  N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial , 2018, Translational Psychiatry.

[56]  P. McGuire,et al.  Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a 1[H]-spectroscopy twin study , 2018, Neuropsychopharmacology.

[57]  Michael F. Green,et al.  ERP indices of performance monitoring and feedback processing in psychosis: A meta-analysis. , 2018, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[58]  A. Egerton,et al.  The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study , 2018, The lancet. Psychiatry.

[59]  J. Théberge,et al.  Putative Astroglial Dysfunction in Schizophrenia: A Meta-Analysis of 1H-MRS Studies of Medial Prefrontal Myo-Inositol , 2018, Front. Psychiatry.

[60]  R. Knight,et al.  Gut microbiome and magnetic resonance spectroscopy study of subjects at ultra-high risk for psychosis may support the membrane hypothesis , 2018, European Psychiatry.

[61]  J. Ragland,et al.  Estimating glutamate and Glx from GABA-optimized MEGA-PRESS: Off-resonance but not difference spectra values correspond to PRESS values , 2018, Psychiatry Research: Neuroimaging.

[62]  A. Egerton,et al.  Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia , 2018, Psychopharmacology.

[63]  R. Bagby,et al.  Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis , 2018, Neuropsychopharmacology.

[64]  K. Prasad,et al.  Neuropil contraction in relation to Complement C4 gene copy numbers in independent cohorts of adolescent-onset and young adult-onset schizophrenia patients–a pilot study , 2018, Translational Psychiatry.

[65]  Tobias Navarro Schröder,et al.  Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages , 2018, eLife.

[66]  Siân E. Robson,et al.  Glutathione and glutamate in schizophrenia: a 7T MRS study , 2018, Molecular Psychiatry.

[67]  S. A. Wijtenburg,et al.  Anterior Cingulate Glutamate and GABA Associations on Functional Connectivity in Schizophrenia , 2018, Schizophrenia bulletin.

[68]  M. Lotfi,et al.  Effect of Adjuvant Electroconvulsive Therapy Compared to Antipsychotic Medication Alone on the Brain Metabolites of Patients with Chronic Schizophrenia: A Proton Magnetic Resonance Spectroscopy Study , 2018, Iranian journal of psychiatry.

[69]  R. Kahn,et al.  Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE) , 2018, Molecular Psychiatry.

[70]  S. A. Wijtenburg,et al.  Glutamatergic Response to Heat Pain Stress in Schizophrenia , 2018, Schizophrenia bulletin.

[71]  Tae Young Lee,et al.  Lower glutamate level in temporo-parietal junction may predict a better response to tDCS in schizophrenia , 2018, Schizophrenia Research.

[72]  C. Montag,et al.  Glutamate Concentration in the Superior Temporal Sulcus Relates to Neuroticism in Schizophrenia , 2018, Front. Psychol..

[73]  R. Mizrahi,et al.  Mitochondrial function in individuals at clinical high risk for psychosis , 2018, Scientific Reports.

[74]  S. A. Wijtenburg,et al.  Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia , 2018, Neuropsychopharmacology.

[75]  Alan A. Wilson,et al.  Interaction between TSPO—a neuroimmune marker—and redox status in clinical high risk for psychosis: a PET–MRS study , 2018, Neuropsychopharmacology.

[76]  G. Remington,et al.  Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study , 2018, Psychiatry Research: Neuroimaging.

[77]  J. Brunelin,et al.  N-Acetyl-Aspartate in the dorsolateral prefrontal cortex in men with schizophrenia and auditory verbal hallucinations: A 1.5 T Magnetic Resonance Spectroscopy Study , 2018, Scientific Reports.

[78]  S. Khushu,et al.  Evidence for regional hippocampal damage in patients with schizophrenia , 2018, Neuroradiology.

[79]  A. Grace,et al.  Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis , 2018, Neuropsychopharmacology.

[80]  S. A. Wijtenburg,et al.  Glutamatergic metabolites among adolescents at risk for psychosis , 2017, Psychiatry Research.

[81]  Dengtang Liu,et al.  Abnormal Concentration of GABA and Glutamate in The Prefrontal Cortex in Schizophrenia.-An in Vivo 1H-MRS Study. , 2017, Shanghai archives of psychiatry.

[82]  R. Bagby,et al.  Glutathione, the Major Redox Regulator, in the Prefrontal Cortex of Individuals at Clinical High Risk for Psychosis , 2017, The international journal of neuropsychopharmacology.

[83]  A. Graff-Guerrero,et al.  Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients , 2017, Biological Psychiatry.

[84]  J. Forsyth,et al.  Mapping the Consequences of Impaired Synaptic Plasticity in Schizophrenia through Development: An Integrative Model for Diverse Clinical Features , 2017, Trends in Cognitive Sciences.

[85]  J. Coyle,et al.  In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time–Averaged Proton Magnetic Resonance Spectroscopy at 4T , 2017, Biological Psychiatry.

[86]  A. Grace,et al.  Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms , 2017, The international journal of neuropsychopharmacology.

[87]  A. Aleman,et al.  Glutamate in dorsolateral prefrontal cortex and auditory verbal hallucinations in patients with schizophrenia: A 1H MRS study , 2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[88]  R. Chan,et al.  In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study , 2017, Schizophrenia Research.

[89]  S. A. Wijtenburg,et al.  Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia , 2017, Front. Psychiatry.

[90]  V. Calhoun,et al.  Risk-Conferring Glutamatergic Genes and Brain Glutamate Plus Glutamine in Schizophrenia , 2017, Front. Psychiatry.

[91]  Hui-feng Duan,et al.  Neuroprotective Effect of Modified Electroconvulsive Therapy for Schizophrenia: A Proton Magnetic Resonance Spectroscopy Study , 2017, The Journal of nervous and mental disease.

[92]  Shao-hua Hu,et al.  Relationships between dorsolateral prefrontal cortex metabolic change and cognitive impairment in first-episode neuroleptic-naive schizophrenia patients , 2017, Medicine.

[93]  G. Dragoi,et al.  Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective , 2017, Biological Psychiatry.

[94]  Jennifer M. Coughlin,et al.  Decoupling of Brain Temperature and Glutamate in Recent Onset of Schizophrenia: A 7T Proton Magnetic Resonance Spectroscopy Study. , 2017, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[95]  J. Machann,et al.  Body and liver fat content and adipokines in schizophrenia: a magnetic resonance imaging and spectroscopy study , 2017, Psychopharmacology.

[96]  René S. Kahn,et al.  7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings , 2017, Biological Psychiatry.

[97]  C. Carter,et al.  Extracellular Free Water and Glutathione in First Episode Psychosis – A Multi-modal Investigation of an Inflammatory Model for Psychosis , 2019, Molecular Psychiatry.

[98]  Dost Öngür,et al.  Brain bioenergetics and redox state measured by 31P magnetic resonance spectroscopy in unaffected siblings of patients with psychotic disorders , 2017, Schizophrenia Research.

[99]  Rolf Gruetter,et al.  N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis , 2017, Schizophrenia bulletin.

[100]  A. Aleman,et al.  Effect of Bilateral Prefrontal rTMS on Left Prefrontal NAA and Glx Levels in Schizophrenia Patients with Predominant Negative Symptoms: An Exploratory Study , 2017, Brain Stimulation.

[101]  A. Aleman,et al.  Association between prefrontal N-acetylaspartate and insight in psychotic disorders , 2017, Schizophrenia Research.

[102]  M. Phillips,et al.  Perisylvian GABA levels in schizophrenia and bipolar disorder , 2017, Neuroscience Letters.

[103]  P. Williamson,et al.  Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T , 2017, BJPsych Open.

[104]  J. Babb,et al.  Metabolic Abnormalities in the Hippocampus of Patients with Schizophrenia: A 3D Multivoxel MR Spectroscopic Imaging Study at 3T , 2016, American Journal of Neuroradiology.

[105]  Chunbo Li,et al.  Reduced γ-Aminobutyric Acid and Glutamate+Glutamine Levels in Drug-Naïve Patients with First-Episode Schizophrenia but Not in Those at Ultrahigh Risk , 2016, Neural plasticity.

[106]  S. A. Wijtenburg,et al.  Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study , 2016, Translational Psychiatry.

[107]  M. Keshavan,et al.  Neuropil pruning in Early-Course Schizophrenia: Immunological, Clinical, and Neurocognitive Correlates. , 2016, Biological psychiatry. Cognitive neuroscience and neuroimaging.

[108]  R. Gruetter,et al.  Genetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis. , 2016, Schizophrenia bulletin.

[109]  Clifford Qualls,et al.  Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample , 2016, Schizophrenia bulletin.

[110]  R. Bartha,et al.  Illness versus substance use effects on the frontal white matter in early phase schizophrenia: A 4Tesla 1H-MRS study , 2016, Schizophrenia Research.

[111]  V. Kaleda,et al.  1H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients , 2016, Doklady Biochemistry and Biophysics.

[112]  A. Egerton,et al.  Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies. , 2016, JAMA psychiatry.

[113]  S. A. Wijtenburg,et al.  Tryptophan Metabolism and White Matter Integrity in Schizophrenia , 2016, Neuropsychopharmacology.

[114]  F. Turkheimer,et al.  Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. , 2016, Schizophrenia bulletin.

[115]  Y. Kıroğlu,et al.  1H-magnetic resonance spectroscopy in first episode and chronic schizophrenia patients. , 2016, Turkish journal of medical sciences.

[116]  Paul G. Unschuld,et al.  Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A 1H MRS Study at 7Tesla , 2016, Schizophrenia Research.

[117]  A. Heguy,et al.  Prefrontal neuronal integrity predicts symptoms and cognition in schizophrenia and is sensitive to genetic heterogeneity , 2016, Schizophrenia Research.

[118]  S. Kühn,et al.  Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia. , 2016, Schizophrenia bulletin.

[119]  A. Graff-Guerrero,et al.  Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. , 2016, Schizophrenia bulletin.

[120]  R. Goetz,et al.  Hypo-metabolism of the rostral anterior cingulate cortex associated with working memory impairment in 18 cases of schizophrenia , 2016, Brain Imaging and Behavior.

[121]  A. Aleman,et al.  Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T 1H-MRS Study , 2016, Scientific Reports.

[122]  A. Lahti,et al.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia , 2016, Schizophrenia Research.

[123]  S. A. Wijtenburg,et al.  Reproducibility of phase rotation stimulated echo acquisition mode at 3T in schizophrenia: Emphasis on glutamine , 2016, Magnetic resonance in medicine.

[124]  S. A. Wijtenburg,et al.  Frontal Glutamate and γ-Aminobutyric Acid Levels and Their Associations With Mismatch Negativity and Digit Sequencing Task Performance in Schizophrenia. , 2016, JAMA psychiatry.

[125]  D. Weinberger,et al.  Prefrontal GABA Levels Measured With Magnetic Resonance Spectroscopy in Patients With Psychosis and Unaffected Siblings. , 2016, The American journal of psychiatry.

[126]  Yifeng Xu,et al.  Comparison of the density of gamma-aminobutyric acid in the ventromedial prefrontal cortex of patients with first-episode psychosis and healthy controls , 2015, Shanghai archives of psychiatry.

[127]  J. Reichenbach,et al.  Associations of hippocampal metabolism and regional brain grey matter in neuroleptic-naïve ultra-high-risk subjects and first-episode schizophrenia , 2015, European Neuropsychopharmacology.

[128]  M. Podgórski,et al.  Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex , 2015, International journal of molecular sciences.

[129]  J. Reichenbach,et al.  Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients , 2015, Schizophrenia Research.

[130]  M. Podgórski,et al.  Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia , 2015, Nutrients.

[131]  M. Podgórski,et al.  Comparison of Metabolite Concentrations in the Left Dorsolateral Prefrontal Cortex, the Left Frontal White Matter, and the Left Hippocampus in Patients in Stable Schizophrenia Treated with Antipsychotics with or without Antidepressants. 1H-NMR Spectroscopy Study , 2015, International journal of molecular sciences.

[132]  Reggie Taylor,et al.  Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task , 2015, npj Schizophrenia.

[133]  A. Graff-Guerrero,et al.  Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy , 2015, The international journal of neuropsychopharmacology.

[134]  Leilei Zheng,et al.  The predictive value of baseline NAA/Cr for treatment response of first-episode schizophrenia: A 1H MRS study , 2015, Neuroscience Letters.

[135]  Shaojia Lu,et al.  The relationship between the alterations in metabolite levels in the dorsolateral prefrontal cortex and clinical symptoms of patients with first-episode schizophrenia: a one year follow-up study , 2015, Oncotarget.

[136]  V. Kaleda,et al.  Characteristics of Diffusion in the Corticospinal Tract of Patients with Early Stage of Schizophrenia: Diffusion Tensor Magnetic Resonance Imaging , 2015, Bulletin of Experimental Biology and Medicine.

[137]  Lynn E Eberly,et al.  Feasibility and reproducibility of neurochemical profile quantification in the human hippocampus at 3 T , 2015, NMR in biomedicine.

[138]  M. Ota,et al.  Effect of l-theanine on glutamatergic function in patients with schizophrenia , 2015, Acta Neuropsychiatrica.

[139]  P Kochunov,et al.  Alterations in frontal white matter neurochemistry and microstructure in schizophrenia: implications for neuroinflammation , 2015, Translational Psychiatry.

[140]  Peter Kochunov,et al.  Medial Frontal GABA is Lower in Older Schizophrenia: A MEGA-PRESS with Macromolecule Suppression Study , 2015, Molecular Psychiatry.

[141]  A. MacDonald,et al.  Brain Correlates of Cognitive Remediation in Schizophrenia: Activation Likelihood Analysis Shows Preliminary Evidence of Neural Target Engagement. , 2015, Schizophrenia bulletin.

[142]  V. Anderson,et al.  Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia , 2015, The international journal of neuropsychopharmacology.

[143]  S. A. Wijtenburg,et al.  Evaluation of Myo-Inositol as a Potential Biomarker for Depression in Schizophrenia , 2015, Neuropsychopharmacology.

[144]  O. Andreassen,et al.  Glutamate as a mediating transmitter for auditory hallucinations in schizophrenia: A 1H MRS study , 2015, Schizophrenia Research.

[145]  M. Phillips,et al.  Investigation of Heschl's gyrus and planum temporale in patients with schizophrenia and bipolar disorder: A proton magnetic resonance spectroscopy study , 2015, Schizophrenia Research.

[146]  René S. Kahn,et al.  GABA and glutamate in schizophrenia: A 7 T 1H-MRS study , 2014, NeuroImage: Clinical.

[147]  H. Yamasue,et al.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. , 2014, Schizophrenia bulletin.

[148]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[149]  R. Murray,et al.  Relationship Between Brain Glutamate Levels and Clinical Outcome in Individuals at Ultra High Risk of Psychosis , 2014, Neuropsychopharmacology.

[150]  J J Bartko,et al.  Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia , 2014, Molecular Psychiatry.

[151]  P. Williamson,et al.  Glutamatergic metabolite correlations with neuropsychological tests in first episode schizophrenia , 2014, Psychiatry Research: Neuroimaging.

[152]  Ullrich K. H. Ecker,et al.  Hippocampal integrity and neurocognition in first-episode schizophrenia: A multidimensional study , 2014, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[153]  R. Murray,et al.  Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function , 2014, Biological Psychiatry.

[154]  Clifford Qualls,et al.  Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. , 2014, JAMA psychiatry.

[155]  J. Gallinat,et al.  Effects of age and sex on the concentrations of glutamate and glutamine in the human brain , 2013, Journal of magnetic resonance imaging : JMRI.

[156]  S. A. Wijtenburg,et al.  In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. , 2013, Schizophrenia bulletin.

[157]  M. Keshavan,et al.  Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy , 2013, Schizophrenia Research.

[158]  C. Hanstock,et al.  3‐T proton magnetic spectroscopy in unmedicated first episode psychosis: A focus on creatine , 2013, Magnetic resonance in medicine.

[159]  Mark S. Bolding,et al.  Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging , 2012, Schizophrenia Research.

[160]  A. Lahti,et al.  Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia , 2012, Neuropsychopharmacology.

[161]  M. Ota,et al.  Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation , 2012, Acta psychiatrica Scandinavica.

[162]  Mark Slifstein,et al.  Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. , 2012, Archives of general psychiatry.

[163]  R. Yoshimura,et al.  Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia , 2012, Neuropsychiatric disease and treatment.

[164]  Deanna M. Barch,et al.  Cognition in schizophrenia: core psychological and neural mechanisms , 2012, Trends in Cognitive Sciences.

[165]  Stephan F. Taylor,et al.  Meta-Analysis of Functional Neuroimaging Studies of Emotion Perception and Experience in Schizophrenia , 2012, Biological Psychiatry.

[166]  B. Ho,et al.  Magnetic resonance spectroscopy of limbic structures displays metabolite differences in young unaffected relatives of schizophrenia probands , 2011, Schizophrenia Research.

[167]  D. Linszen,et al.  Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis , 2011, Biological Psychiatry.

[168]  T. van Amelsvoort,et al.  Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome , 2011, PloS one.

[169]  Ravi S. Menon,et al.  Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia , 2011, British Journal of Psychiatry.

[170]  J. Walecki,et al.  Proton Magnetic Resonance Spectroscopy Study of Brain Metabolite Changes after Antipsychotic Treatment , 2011, Pharmacopsychiatry.

[171]  A. Graff-Guerrero,et al.  Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis , 2011, Neuropsychopharmacology.

[172]  J. Lauriello,et al.  Glutamate as a Marker of Cognitive Function in Schizophrenia: A Proton Spectroscopic Imaging Study at 4 Tesla , 2011, Biological Psychiatry.

[173]  Nick F. Ramsey,et al.  Left dorsolateral prefrontal cortex dysfunction in medication-naive schizophrenia , 2010, Schizophrenia Research.

[174]  Dost Öngür,et al.  Elevated Gamma-Aminobutyric Acid Levels in Chronic Schizophrenia , 2010, Biological Psychiatry.

[175]  J. Lauriello,et al.  1H-MRS at 4 Tesla in minimally treated early schizophrenia , 2010, Molecular Psychiatry.

[176]  Wolfgang Viechtbauer,et al.  Outlier and influence diagnostics for meta‐analysis , 2010, Research synthesis methods.

[177]  Tyrone D. Cannon,et al.  Proton MRS in twin pairs discordant for schizophrenia , 2010, Molecular Psychiatry.

[178]  Takayuki Obata,et al.  Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: A preliminary study , 2010, NeuroImage.

[179]  Andreas Meyer-Lindenberg,et al.  MR spectroscopic evaluation of N-acetylaspartate's T2 relaxation time and concentration corroborates white matter abnormalities in schizophrenia , 2009, NeuroImage.

[180]  M. Keshavan,et al.  Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: A 1H spectroscopy study , 2009, Schizophrenia Research.

[181]  Philip K. McGuire,et al.  Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume , 2009, Biological Psychiatry.

[182]  Alex Fornito,et al.  Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. , 2009, Schizophrenia bulletin.

[183]  M. Minzenberg,et al.  Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. , 2009, Archives of general psychiatry.

[184]  J. Kwon,et al.  Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: Investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus , 2009, Schizophrenia Research.

[185]  Masafumi Harada,et al.  Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS) , 2009, Schizophrenia Research.

[186]  J. Walecki,et al.  Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia. , 2009, Medical science monitor : international medical journal of experimental and clinical research.

[187]  Volker Arolt,et al.  Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy , 2008, Schizophrenia Research.

[188]  Alan N. Francis,et al.  White Matter Alterations in Deficit Schizophrenia , 2008, Neuropsychopharmacology.

[189]  Dost Öngür,et al.  Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania , 2008, Biological Psychiatry.

[190]  C. Pantelis,et al.  A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis , 2008, Schizophrenia Research.

[191]  V. Haroutunian,et al.  Altered Vesicular Glutamate Transporter Expression in the Anterior Cingulate Cortex in Schizophrenia , 2008, Biological Psychiatry.

[192]  N. Rüsch,et al.  Neurochemical and structural correlates of executive dysfunction in schizophrenia , 2008, Schizophrenia Research.

[193]  C. Hanstock,et al.  Elevated 3T proton MRS glutamate levels associated with poor Continuous Performance Test (CPT-0X) scores and genetic risk for schizophrenia , 2008, Schizophrenia Research.

[194]  Linda Chang,et al.  Brain Metabolite Abnormalities in the White Matter of Elderly Schizophrenic Subjects: Implication for Glial Dysfunction , 2007, Biological Psychiatry.

[195]  A. Kersting,et al.  Cognitive Impairment and in Vivo Metabolites in First-episode Neuroleptic-naive and Chronic Medicated Schizophrenic Patients: a Proton Magnetic Resonance Spectroscopy Study , 2006 .

[196]  Dennis Velakoulis,et al.  Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: A proton magnetic resonance spectroscopy study at 3 T , 2007, Schizophrenia Research.

[197]  Jeffrey A. Stanley,et al.  Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: A single-voxel 1H spectroscopy study , 2007, Schizophrenia Research.

[198]  K. Uğurbil,et al.  Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.

[199]  Jeffrey A Lieberman,et al.  Measurement of Brain Metabolites by 1H Magnetic Resonance Spectroscopy in Patients with Schizophrenia: A Systematic Review and Meta-Analysis , 2005, Neuropsychopharmacology.

[200]  Martin Büchert,et al.  Increased Prefrontal and Hippocampal Glutamate Concentration in Schizophrenia: Evidence from a Magnetic Resonance Spectroscopy Study , 2005, Biological Psychiatry.

[201]  A. Kersting,et al.  Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study , 2005, Schizophrenia Research.

[202]  C. Hanstock,et al.  3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. , 2004, The American journal of psychiatry.

[203]  Ravi S. Menon,et al.  Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. , 2003, The American journal of psychiatry.

[204]  H. Yamasue,et al.  Drug-induced parkinsonism in relation to choline-containing compounds measured by 1H-MR spectroscopy in putamen of chronically medicated patients with schizophrenia. , 2003, The international journal of neuropsychopharmacology.

[205]  Ravi S. Menon,et al.  Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. , 2002, The American journal of psychiatry.

[206]  D van Ormondt,et al.  Cramér–Rao bounds: an evaluation tool for quantitation , 2001, NMR in biomedicine.

[207]  Thomas G Schulze,et al.  Decreased frontal lobe ratio of N-acetyl aspartate to choline in familial schizophrenia: a proton magnetic resonance spectroscopy study , 2000, Neuroscience Letters.

[208]  Marc Laruelle,et al.  Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies , 2000, Psychiatry Research: Neuroimaging.

[209]  Robert Bartha,et al.  A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients , 1999, Biological Psychiatry.

[210]  J. Levitt,et al.  Preliminary study of frontal lobe 1H MR spectroscopy in childhood‐onset schizophrenia , 1998, Journal of magnetic resonance imaging : JMRI.

[211]  R W Neufeld,et al.  Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. , 1997, Archives of general psychiatry.

[212]  T. Ernst,et al.  Elimination of artifacts in short echo time 1H MR spectroscopy of the frontal lobe , 1996, Magnetic resonance in medicine.

[213]  B. Choe,et al.  Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. , 1996, Investigative radiology.

[214]  R. Lenkinski,et al.  1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. , 1994, Academic radiology.

[215]  R. Kauppinen,et al.  Compartmentation of cerebral glutamate in situ as detected by 1H/13C n.m.r. , 1994, The Biochemical journal.

[216]  R. Kauppinen,et al.  1H Nuclear Magnetic Resonance Spectroscopy Study of Cerebral Glutamate in an Ex Vivo Brain Preparation of Guinea Pig , 1993, Journal of neurochemistry.

[217]  R. Kauppinen,et al.  Nondestructive Detection of Glutamate by 1H Nuclear Magnetic Resonance Spectroscopy in Cortical Brain Slices from the Guinea Pig: Evidence for Changes in Detectability During Severe Anoxic Insults , 1991, Journal of neurochemistry.

[218]  S. A. Wijtenburg,et al.  Sleep quality is related to brain glutamate and symptom severity in schizophrenia. , 2019, Journal of psychiatric research.

[219]  T. Gawne,et al.  7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia , 2019, Schizophrenia bulletin.

[220]  D. Lewis,et al.  Mapping pathologic circuitry in schizophrenia. , 2018, Handbook of clinical neurology.

[221]  J. Coyle,et al.  The Role of Serine Racemase in the Pathophysiology of Brain Disorders. , 2018, Advances in pharmacology.

[222]  R. Gruetter,et al.  Cannabis use in early psychosis is associated with reduced glutamate levels in the prefrontal cortex , 2017, Psychopharmacology.

[223]  Danny J. J. Wang,et al.  Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study , 2017, Neuropsychopharmacology.

[224]  M. Simu,et al.  The effect of neurobiological changes in the brain of children with schizophrenia, ultra high-risk for psychosis and epilepsy: clinical correlations with EEG and neuroimagistic abnormalities. , 2017, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[225]  Ann K. Shinn,et al.  Redox Dysregulation in Schizophrenia Revealed by in vivo NAD+/NADH Measurement , 2017, Schizophrenia bulletin.

[226]  M. Puiu,et al.  The prognostic and clinical significance of neuroimagistic and neurobiological vulnerability markers in correlation with the molecular pharmacogenetic testing in psychoses and ultra high-risk categories. , 2016, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[227]  Peter R Luijten,et al.  Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. , 2013, Schizophrenia bulletin.

[228]  Michael Wagner,et al.  N-acetylaspartylglutamate (NAAG) and N-acetylaspartate (NAA) in patients with schizophrenia. , 2013, Schizophrenia bulletin.

[229]  Bita Moghaddam,et al.  From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment , 2012, Neuropsychopharmacology.

[230]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[231]  田吉 伸哉,et al.  Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS) , 2009 .

[232]  P. Dokkum,et al.  The nature of , 2006 .

[233]  P. Williamson,et al.  An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. , 1996, Schizophrenia bulletin.